HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients’ survival

Background Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8th edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. Material and methods The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7th edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16INK4a or HPV-mRNA), p16INK4a positivity alone or the combination of HPV-DNA/p16INK4a positivity as diagnostic tests. Results A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16INK4a or HPV-mRNA), 83 (10.5%) were p16INK4a positive and 58 (7.4%) were double positive for HPV-DNA/p16INK4a. ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16INK4a-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. Conclusion HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients’ survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials.

[1]  M. Rietbergen,et al.  Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Dietz,et al.  The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de‐escalate treatment regimens in p16‐positive oropharyngeal cancer patients? , 2017, International Journal of Cancer.

[3]  L. Alemany,et al.  Human papillomavirus-related oropharyngeal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  C. Chung,et al.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Garden,et al.  Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Poljak,et al.  HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. , 2016, Journal of the National Cancer Institute.

[7]  Shao Hui Huang,et al.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. , 2016, The Lancet. Oncology.

[8]  John Cho,et al.  Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Konge,et al.  Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review , 2014, British Journal of Cancer.

[10]  M. Rietbergen,et al.  Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Clavel,et al.  Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France--The EDiTH VI study. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[13]  C. R. Leemans,et al.  A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen , 2007, International journal of cancer.

[14]  M. Zahurak,et al.  Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma , 2005, Clinical Cancer Research.

[15]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[16]  F. Alawi,et al.  Human Papillomavirus and Oropharyngeal Cancer. , 2018, Dental clinics of North America.

[17]  S. Franceschi,et al.  Biological activity of probable/possible high‐risk human papillomavirus types in cervical cancer , 2013, International journal of cancer.

[18]  M. von Knebel Doeberitz,et al.  Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta‐analysis , 2017, International journal of cancer.